Huang B G, Bobek M
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Carbohydr Res. 1998 Jun;308(3-4):319-28. doi: 10.1016/s0008-6215(98)00098-6.
7-(6-amino-6-deoxy-beta-D-glucofuranosyl)-5-cyanopyrrolo[2,3 -d]pyrimidine (22) and 7-(3-amino-methyl-3-deoxy-beta-D-allofuranosyl)-5- cyanopyrrolo[2,3-d]pyrimidine (28) were synthesized by sequentially coupling silylated 4-amino-6-bromo-5- cyanopyrrolo[2,3-d]pyrimidine with the corresponding protected sugars 9 and 17, followed by deblocking and catalytic hydrogenation. Conversion of the 5-nitrile in 22 and 28 into a carboxamide gave the corresponding sangivamycin derivatives 23 and 29. Whereas 5'-aminomethyl nucleosides 22 and 23 inhibited the growth of four different human tumor cell lines at microM concentrations, the 3'-aminomethyl analogs 28 and 29 were much less active against these cells.
7-(6-氨基-6-脱氧-β-D-葡萄糖呋喃糖基)-5-氰基吡咯并[2,3-d]嘧啶(22)和7-(3-氨基甲基-3-脱氧-β-D-阿洛呋喃糖基)-5-氰基吡咯并[2,3-d]嘧啶(28)的合成方法是,先将硅烷化的4-氨基-6-溴-5-氰基吡咯并[2,3-d]嘧啶与相应的保护糖9和17依次偶联,然后进行脱保护和催化氢化反应。将22和28中的5-腈基转化为羧酰胺,得到相应的桑吉瓦霉素衍生物23和29。5'-氨基甲基核苷22和23在微摩尔浓度下可抑制四种不同人类肿瘤细胞系的生长,而3'-氨基甲基类似物28和29对这些细胞的活性则低得多。